Skip to content
2000
Volume 14, Issue 1
  • ISSN: 1574-8847
  • E-ISSN: 2212-3938

Abstract

Developing new biologics has led to regulations and norms aimed at guaranteeing their safety, quality and effectiveness, in terms of marketing, prescription, use, interchangeability and switching. Biologics are of great importance in treating patients suffering from rheumatic, autoimmune, inflammatory and neoplastic diseases. The expiry/lapse of reference biologics or originators’ patents has meant that developing biosimilars involves accompanying legal requirements for their approval in countries worldwide. This paper has thus approached the situation of biosimilar regulation worldwide, the pertinent technical concepts and regulatory differences in some countries of interest.

Loading

Article metrics loading...

/content/journals/ccp/10.2174/1574884713666181025142928
2019-04-01
2025-07-03
Loading full text...

Full text loading...

/content/journals/ccp/10.2174/1574884713666181025142928
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test